Sernova and Seraxis to Participate in Noble Capital Markets Conference
News related to:Sernova Biotherapeutics · 2 min read
TORONTO and GERMANTOWN, Md., Sept. 25, 2026 /CourierPR/ -- Sernova Biotherapeutics, a clinical-stage regenerative medicine company focused on developing cell therapies for type 1 diabetes (T1D), will participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, October 1, at 1:30 p.m. Eastern Time. The event will feature a joint presentation by Jonathan Rigby, President and CEO of Sernova, and Will Rust, Ph.D., President and CEO of Seraxis Holdings, Inc. (Seraxis).
The presentation will focus on the companies' proposed merger to form BetaNova Biotherapeutics, a U.S.-domiciled, clinical-stage biotechnology company. The merger aims to combine Seraxis’ stem cell-derived pancreatic islet cell programs and in-house cGMP manufacturing capabilities with Sernova’s clinically validated, implantable and retrievable Cell Pouch Bio-hybrid Organ. This integration is expected to create an integrated platform spanning therapeutic cells, manufacturing, and cell delivery.
According to the press release, the companies announced a definitive agreement on September 8, 2026, to combine their businesses and technologies. The proposed merger is anticipated to close in November 2026, subject to shareholder, court, TSX, and other customary approvals and closing conditions. The agreement brings together Seraxis’ SR-02 and SR-03 stem cell-derived pancreatic islet programs and scalable cGMP manufacturing with Sernova’s Cell Pouch Bio-hybrid Organ, creating a comprehensive approach to T1D cell replacement.
The live virtual presentation will include an interactive Q&A with questions from attendees. Qualified investors may also request scheduled one-on-one meetings with members of the Sernova and Seraxis management teams. A replay of the presentation will be available for 90 days following the event through Sernova’s website and as part of a complete catalog of presentations available on Channelchek.
Sernova Biotherapeutics is a clinical-stage regenerative medicine company developing cell-based therapies for type 1 diabetes. Its Cell Pouch Bio-hybrid Organ is a clinically validated, implantable and retrievable cell containment device designed to provide a vascularized environment for therapeutic cells and support cell survival, engraftment, and function.
Seraxis is a clinical-stage company that develops stem cell-derived pancreatic islets and scalable cGMP manufacturing processes. Seraxis’ mission is to demonstrate safety and potency of its islets in T1D patients without immune suppression therapy. Its lead allogeneic product, SR-02, is IND-cleared and will be paired with an immune tolerizing strategy. Seraxis’ follow-on product SR-03 adds gene edits to SR-02 that increase compatibility with the host and potentially enhance long-term engraftment without immune suppression. Seraxis operates in-house cGMP manufacturing capabilities to support scalable production of its cell therapies.
The companies aim to advance a differentiated approach to T1D cell replacement, leveraging the complementary technologies and strategies of both organizations. The merger is expected to significantly enhance their combined capabilities and accelerate the development of innovative cell therapies for T1D patients.